Soligenix, Inc. (SNGX)

NASDAQ: SNGX · Real-Time Price · USD
3.380
+0.020 (0.60%)
At close: Aug 22, 2025, 4:00 PM
3.439
+0.059 (1.75%)
After-hours: Aug 22, 2025, 4:07 PM EDT
0.60%
Market Cap14.46M
Revenue (ttm)n/a
Net Income (ttm)-10.36M
Shares Out 4.29M
EPS (ttm)-3.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume583,212
Open3.250
Previous Close3.360
Day's Range3.210 - 3.440
52-Week Range1.090 - 6.230
Beta1.96
AnalystsStrong Buy
Price Target6.00 (+77.78%)
Earnings DateAug 14, 2025

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 1987
Employees 16
Stock Exchange NASDAQ
Ticker Symbol SNGX
Full Company Profile

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.

Financial Statements

Analyst Summary

According to one analyst, the rating for SNGX stock is "Strong Buy" and the 12-month stock price target is $6.0.

Price Target
$6.0
(77.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Why Is Soligenix Stock Soaring On Monday?

Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet's Disease.

4 days ago - Benzinga

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha...

4 days ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

8 days ago - PRNewsWire

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeuti...

14 days ago - GlobeNewsWire

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...

22 days ago - PRNewsWire

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

6 weeks ago - PRNewsWire

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Active Ingredient Manufacturing Transfer to the U.S. Complete  PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

7 weeks ago - PRNewsWire

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

2 months ago - GlobeNewsWire

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the ...

4 months ago - PRNewsWire

IBN Initiates Coverage of Soligenix Inc.

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare disea...

5 months ago - GlobeNewsWire

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™  compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

5 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

5 months ago - PRNewsWire

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc....

6 months ago - PRNewsWire

Soligenix to Present at BIO CEO & Investor Conference

PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

7 months ago - PRNewsWire

Soligenix to Present at Upcoming Investor Conferences

PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

7 months ago - PRNewsWire

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmac...

7 months ago - PRNewsWire

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

FLASH 2  Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on dev...

8 months ago - PRNewsWire

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph...

9 months ago - PRNewsWire

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical...

9 months ago - PRNewsWire

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

10 months ago - Accesswire

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

10 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

10 months ago - PRNewsWire

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (S...

10 months ago - PRNewsWire

Soligenix Invited to Present at Upcoming Investor Conferences

PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

11 months ago - PRNewsWire